Oyster Therapeutics announces the closing of a $60 million Series A-2 financing to advance targeted protein degraders for Alzheimer’s and other neurodegenerative diseases.
Amount Raised
$60 Million
Round Type
Series A
Greater LondonBiotechnologyHealth CareTherapeuticsDescription
Oyster Therapeutics, formerly known as Kesmalea Therapeutics, has closed a $60 million Series A-2 financing round. The funding will be used to advance their next-generation targeted protein degraders. This financing supports their mission to develop treatments for Alzheimer’s and other neurodegenerative diseases. The company has also rebranded as part of their growth strategy.
Who to call at Oyster Therapeutics, and when
A new round usually means Oyster Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Oyster Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Oyster Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Oyster Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Oyster Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansOyster Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.